Search

Your search keyword '"Heimbach, J."' showing total 296 results
Start Over Author "Heimbach, J."

Refine your results

more »

more »

more »

more »
296 results on '"Heimbach, J."'

1. Financial toxicity in living donor liver transplantation: A call to action for financial neutrality

Author

Testa, G., Gupta, A., Lee, S., Fricker, Z., Hashimoto, K., Kwon, D., Emond, J., Fox, A., Samstein, B., Brown, R., Rosenblatt, R., Kubal, A., Gilroy, R., King, E., Heimbach, J., Taner, T., Watt, K., Chacko, K., von Ahrens, D., Fortune, B., Florman, S., Schiano, T., Liapakis, A., Griesemer, A., Orandi, B., Caicedo, J., Dietch, Z., Ganger, D., Duarte, A., Ravindra, K., Kappus, M., Melcher, M., Bhan, I., Tholey, D., Kaplan, A., Anderson, B., Selzner, N., Roberts, J.P., Pillai, A., DiSabato, D., Pomfret, E., Jackson, W., Maluf, D., Sonnenday, C., Bloom, P., Haakinson, D., Chinnakotla, S., Aby, E., Olthoff, K., Abu-Gazala, S., Bittermann, T., Abt, P., Humar, A., Ganesh, S., Bambha, K., Biggins, S., Hernandez-Alejandro, R., Tomiyama, K., Emamaullee, J., Kaur, N., Han, H., Klair, T., Yamaguchi, S., Cullen, J., Baker, T., Kim, R., Goldaracena, N., Sturdevant, M., Kwon, Y., Garonzik-Wang, J., Al-Adra, D., Shingina, A., Rizzari, M., Mulligan, D., Rubman, S., Batra, R., Batisti, J., Kaplan, Alyson, Aby, Elizabeth S., Scott, Sonia, Sonnenday, Christopher, Fox, Alyson, Mathur, Amit, Olthoff, Kim, Heimbach, Julie, Ladin, Keren, and Emamaullee, Juliet

Published
2024
Full Text
View/download PDF

2. Assessment of long‐term outcomes post living liver donation highlights the importance of scientific integrity when presenting transplant registry data

Author

Emamaullee, Juliet, Heimbach, Julie K, Olthoff, Kim M, Pomfret, Elizabeth A, Roberts, John P, Selzner, Nazia, Testa, G, Gupta, A, Lee, S, Hashimoto, K, Kwon, D, Emond, J, Griesemer, A, Fox, A, Kaplan, A, Samstein, B, Halazun, K, Brown, R, Kubal, A, Gilroy, R, Davalos, M Rodriguez‐, King, E, Heimbach, J, Watt, K, Florman, S, Schiano, T, Caicedo, J, Dietch, Z, Ganger, D, Kirchner, V, Anderson, B, Shapiro, J, Roberts, J, Pillai, A, Maluf, D, Martins, PN, Sonnenday, C, Chinnakotla, S, Olthoff, K, Bittermann, T, Abt, P, Humar, A, Ganesh, S, Hernandez‐Alejandro, R, Tomiyama, K, Levstik, M, Emamaullee, J, Kaur, N, Genyk, Y, Klair, T, Yamaguchi, S, Baker, T, Kim, R, Goldaracena, N, Bambha, K, Biggins, S, Sturdevant, M, Garonzik‐Wang, J, Al‐Adra, D, Shingina, A, Alexopoulos, S, Mulligan, D, Emre, S, Liapakis, A, Rubman, S, Batra, R, Taner, T, Melcher, M, DiSabato, D, Pomfret, E, Jackson, W, Han, H, and Montenovo, M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Organ Transplantation, Digestive Diseases, Transplantation, Clinical Research, Chronic Liver Disease and Cirrhosis, Rare Diseases, Liver Disease, Humans, Liver, Liver Transplantation, Living Donors, Registries, Transplants, living donation, living donor liver transplantation, NALLDIG Consortium*, Medical and Health Sciences, Surgery, Clinical sciences
Abstract

Living donor liver transplantation has expanded in recent years, particularly in North America. As experience with this procedure has matured over the last 25 years, centers are increasingly faced with potential living donors who are more medically complex. As donors move through the evaluation process, completing the informed consent process continues to be challenged by a paucity of granular data demonstrating long-term outcomes and overall safety specifically in the otherwise "healthy" living liver donor population. Two recently published studies examined long-term outcomes post-living liver donation using Korean registry data and reported similar results, with excellent overall survival when compared to appropriately matched controls. However, the authors of these studies were presented differently, with one reporting an alarmist view based on one aspect of a suboptimal analysis approach using an inappropriate comparator group. Herein, the North American Living Liver Donor Innovation Group (NALLDIG) consortium discusses these two studies and their potential impact on living liver donation in North America, ultimately highlighting the importance of scientific integrity in data presentation and dissemination when using transplant registry data.

Published
2022

4. Financial toxicity in living donor liver transplantation: A call to action for financial neutrality

Author

Kaplan, Alyson, Aby, Elizabeth S., Scott, Sonia, Sonnenday, Christopher, Fox, Alyson, Mathur, Amit, Olthoff, Kim, Heimbach, Julie, Ladin, Keren, Emamaullee, Juliet, Testa, G., Gupta, A., Lee, S., Fricker, Z., Hashimoto, K., Kwon, D., Emond, J., Fox, A., Samstein, B., Brown, R., Rosenblatt, R., Kubal, A., Gilroy, R., King, E., Heimbach, J., Taner, T., Watt, K., Chacko, K., von Ahrens, D., Fortune, B., Florman, S., Schiano, T., Liapakis, A., Griesemer, A., Orandi, B., Caicedo, J., Dietch, Z., Ganger, D., Duarte, A., Ravindra, K., Kappus, M., Melcher, M., Bhan, I., Tholey, D., Kaplan, A., Anderson, B., Selzner, N., Roberts, J.P., Pillai, A., DiSabato, D., Pomfret, E., Jackson, W., Maluf, D., Sonnenday, C., Bloom, P., Haakinson, D., Chinnakotla, S., Aby, E., Olthoff, K., Abu-Gazala, S., Bittermann, T., Abt, P., Humar, A., Ganesh, S., Bambha, K., Biggins, S., Hernandez-Alejandro, R., Tomiyama, K., Emamaullee, J., Kaur, N., Han, H., Klair, T., Yamaguchi, S., Cullen, J., Baker, T., Kim, R., Goldaracena, N., Sturdevant, M., Kwon, Y., Garonzik-Wang, J., Al-Adra, D., Shingina, A., Rizzari, M., Mulligan, D., Rubman, S., Batra, R., and Batisti, J.

Abstract

After 2 decades of limited growth, living donor liver transplant (LDLT) has been increasingly accepted as a promising solution to the growing organ shortage in the US. With experience, LDLT offers superior graft and patient survival with low rates of rejection. However, not all waitlisted patients have equal access to LDLT, with financial toxicity representing a substantial barrier. Potential living liver donors face indirect, direct, and opportunity costs associated with donation as well as insurance-based discrimination and variable employer leave policies. There are multiple potential national, local, and patient-centered solutions to address some of the cost-related issues associated with living LDLT. These include standardization of employer leave policies, creation of federal and state-led tax relief programs, optimization of National Living Donor Assistance Center use, engagement of independent living donor advocates, creation of financial toolkits, and encouragement of recipient or donor-led fundraising. In this piece, members of the North American Living Liver Donation Group, a consortium of 37 LDLT programs, explore these financial challenges and discuss solutions to achieve financial neutrality, where individuals can donate free from financial constraints or gains. As a community, it is imperative that we confront factors driving financial toxicity to improve equity and access to LDLT.

Published
2024
Full Text
View/download PDF

8. Encompassing new use cases - level 3.0 of the HUPO-PSI format for molecular interactions

Author

Sivade (Dumousseau), M., Alonso-López, D., Ammari, M., Bradley, G., Campbell, N. H., Ceol, A., Cesareni, G., Combe, C., De Las Rivas, J., del-Toro, N., Heimbach, J., Hermjakob, H., Jurisica, I., Koch, M., Licata, L., Lovering, R. C., Lynn, D. J., Meldal, B. H. M., Micklem, G., Panni, S., Porras, P., Ricard-Blum, S., Roechert, B., Salwinski, L., Shrivastava, A., Sullivan, J., Thierry-Mieg, N., Yehudi, Y., Van Roey, K., and Orchard, S.

Published
2018
Full Text
View/download PDF

10. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Author

Banales, J, Marin, J, Lamarca, A, Rodrigues, P, Khan, S, Roberts, L, Cardinale, V, Carpino, G, Andersen, J, Braconi, C, Calvisi, D, Perugorria, M, Fabris, L, Boulter, L, Macias, R, Gaudio, E, Alvaro, D, Gradilone, S, Strazzabosco, M, Marzioni, M, Coulouarn, C, Fouassier, L, Raggi, C, Invernizzi, P, Mertens, J, Moncsek, A, Rizvi, S, Heimbach, J, Koerkamp, B, Bruix, J, Forner, A, Bridgewater, J, Valle, J, Gores, G, Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ, Banales, J, Marin, J, Lamarca, A, Rodrigues, P, Khan, S, Roberts, L, Cardinale, V, Carpino, G, Andersen, J, Braconi, C, Calvisi, D, Perugorria, M, Fabris, L, Boulter, L, Macias, R, Gaudio, E, Alvaro, D, Gradilone, S, Strazzabosco, M, Marzioni, M, Coulouarn, C, Fouassier, L, Raggi, C, Invernizzi, P, Mertens, J, Moncsek, A, Rizvi, S, Heimbach, J, Koerkamp, B, Bruix, J, Forner, A, Bridgewater, J, Valle, J, Gores, G, Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, and Gores GJ

Abstract

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.

Published
2020

33. ICU and Hospital Outcomes of Patients with Hepatopulmonary Syndrome Undergoing Liver Transplantation

Author

Aragon Pinto, C.N., primary, Iyer, V.N., additional, Albitar, H.A.H., additional, Almodallal, Y.A., additional, DuBrock, H.M., additional, Cajigas, H.R., additional, Heimbach, J., additional, Rosen, C., additional, Taner, T., additional, Nyberg, S., additional, Vargas, H., additional, Cartin-Ceba, R., additional, Keaveny, A., additional, Krowka, M.J., additional, and Gallo de Moraes, A., additional

Published
2020
Full Text
View/download PDF

35. Short and Long Termoxygenation Outcomes After Liver Transplantation for Hepatopulmonary Syndrome

Author

Aragon Pinto, C.N., primary, Gallo de Moraes, A., additional, Albitar, H.A.H., additional, Almodallal, Y.A., additional, DuBrock, H.M., additional, Cajigas, H.R., additional, Heimbach, J., additional, Rosen, C., additional, Taner, T., additional, Nyberg, S., additional, Vargas, H., additional, Cartin-Ceba, R., additional, Krowka, M.J., additional, Keaveny, A., additional, and Iyer, V.N., additional

Published
2020
Full Text
View/download PDF

41. Transplant Oncology in Primary and Metastatic Liver Tumor: Principles, Evidence and Opportunities

Author

Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, Greten TF, Pugh TJ, Dawson LA, and Mazzaferro V

Subjects
surgical oncology, surgical procedures, operative, oncology, transplant oncology, transplantation
Abstract

Transplant oncology defines any application of transplant medicine and surgery aimed at improving cancer patients' survival and/or quality of life. In practice, liver transplantation for selected hepato-biliary cancers is the only solid organ transplant with demonstrated efficacy in curing cancer. Four are the proposed future contributions of transplant oncology in hepato-biliary cancer (4-e). 1. evolutionary approach to cancer care that includes liver transplantation; 2. elucidation of self and non-self recognition systems, by linking tumor and transplant immunology; 3. exploration of innovative endpoints both in clinical and experimental settings taking advantage from the access to the entire liver explant; 4. extension of surgical limitation in the multidisciplinary approach to hepato-biliary oncology. The aim of this review is to define the principles of transplant oncology that may be applied to hepato-biliary cancer treatment and research, attempting to balance current evidences with future opportunities.

Published
2020

48. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Author

Banales, J.M., Marin, J.J.G., LaMarca, A., Rodrigues, P.M., Khan, S.A., Roberts, L.R., Cardinale, V., Carpino, G., Andersen, J.B., Braconi, C., Calvisi, D.F., Perugorria, M.J., Fabris, L., Boulter, L, Macias, R.I.R., Gaudio, E., Alvaro, D., Gradilone, S.A., Strazzabosco, M, Marzioni, M., Coulouarn, C., Fouassier, L., Raggi, C., Invernizzi, P, Mertens, J.C., Moncsek, A., Rizvi, S., Heimbach, J., Groot Koerkamp, B. (Bas), Bruix, J. (J.), Forner, A., Bridgewater, J., Valle, J.W., Gores, G.J. (Gregory), Banales, J.M., Marin, J.J.G., LaMarca, A., Rodrigues, P.M., Khan, S.A., Roberts, L.R., Cardinale, V., Carpino, G., Andersen, J.B., Braconi, C., Calvisi, D.F., Perugorria, M.J., Fabris, L., Boulter, L, Macias, R.I.R., Gaudio, E., Alvaro, D., Gradilone, S.A., Strazzabosco, M, Marzioni, M., Coulouarn, C., Fouassier, L., Raggi, C., Invernizzi, P, Mertens, J.C., Moncsek, A., Rizvi, S., Heimbach, J., Groot Koerkamp, B. (Bas), Bruix, J. (J.), Forner, A., Bridgewater, J., Valle, J.W., and Gores, G.J. (Gregory)

Abstract

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.

Published
2020
Full Text
View/download PDF

49. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Author

Banales, JM, Marin, JJG, LaMarca, A, Rodrigues, PM, Khan, SA, Roberts, LR, Cardinale, V, Carpino, G, Andersen, JB, Braconi, C, Calvisi, DF, Perugorria, MJ, Fabris, L, Boulter, L, Macias, RIR, Gaudio, E, Alvaro, D, Gradilone, SA, Strazzabosco, M, Marzioni, M, Coulouarn, C, Fouassier, L, Raggi, C, Invernizzi, P, Mertens, JC, Moncsek, A, Rizvi, S, Heimbach, J, Groot Koerkamp, B, Bruix, J, Forner, A, Bridgewater, J, Valle, JW, Gores, GJ, Banales, JM, Marin, JJG, LaMarca, A, Rodrigues, PM, Khan, SA, Roberts, LR, Cardinale, V, Carpino, G, Andersen, JB, Braconi, C, Calvisi, DF, Perugorria, MJ, Fabris, L, Boulter, L, Macias, RIR, Gaudio, E, Alvaro, D, Gradilone, SA, Strazzabosco, M, Marzioni, M, Coulouarn, C, Fouassier, L, Raggi, C, Invernizzi, P, Mertens, JC, Moncsek, A, Rizvi, S, Heimbach, J, Groot Koerkamp, B, Bruix, J, Forner, A, Bridgewater, J, Valle, JW, and Gores, GJ

Published
2020

50. Long-term outcomes of the octogenarian donor liver recipient: The era of the new centurion

Author

Schneider S, Díaz Jaime F, Mara K, Dierkhising R, Heimbach J, Watt KD, and Berenguer M

Subjects
cardiovascular, donor age, elder, liver transplantation, metabolic, survival
Abstract

Studies have suggested transplantation using older donor livers results in similar short-term outcomes as younger donor livers; however, little data exist on long-term patient/graft outcomes of the octogenarian liver recipient.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results